{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:31:51Z","timestamp":1789835511170,"version":"4.0.1"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005247","name":"The University of British Columbia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000261","name":"MS Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000261","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011873","name":"Multiple Sclerosis Scientific Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011873","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jaut.2026.103526","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T11:48:20Z","timestamp":1769168900000},"page":"103526","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Interventional studies targeting the prodromal or preclinical phase of immune-mediated disease to benefit patient outcomes: a scoping review"],"prefix":"10.1016","volume":"159","author":[{"given":"Kara","family":"Moscovitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daivat","family":"Bhavsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5804-2535","authenticated-orcid":false,"given":"Helen","family":"Tremlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaut.2026.103526_bib1","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nrg.2015.33","article-title":"Autoimmune diseases\u2014connecting risk alleles with molecular traits of the immune system","volume":"17","author":"Gutierrez-Arcelus","year":"2016","journal-title":"Nat. Rev. Genet."},{"issue":"978","key":"10.1016\/j.jaut.2026.103526_bib2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/pgmj.2006.052688","article-title":"Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution","volume":"83","author":"Kuek","year":"2007","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.jaut.2026.103526_bib3","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/S0140-6736(23)00457-9","article-title":"Incidence, prevalence, and co-occurrence of autoimmune disorders over time a population-based cohort study of 22 million individuals in the UK","volume":"401","author":"Conrad","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2026.103526_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2022.102266","article-title":"The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention","volume":"80","author":"Miller","year":"2023","journal-title":"Curr. Opin. Immunol."},{"issue":"5","key":"10.1016\/j.jaut.2026.103526_bib5","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/art.42775","article-title":"Declining incidence of systemic lupus erythematosus in Norway 1999\u20132017: data from a population cohort identified by International Classification of diseases, 10th revision code and verified by classification","volume":"76","author":"Haukeland","year":"2024","journal-title":"Arthritis Rheumatol."},{"issue":"8","key":"10.1016\/j.jaut.2026.103526_bib6","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/acr2.11585","article-title":"Epidemiology and damage accrual of systemic lupus erythematosus in central Sweden: a single\u2010center population\u2010based cohort study over 14 years from \u00d6sterg\u00f6tland county","volume":"5","author":"Arkema","year":"2023","journal-title":"ACR Open Rheumatol"},{"issue":"1","key":"10.1016\/j.jaut.2026.103526_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/ard.2004.023044","article-title":"Is rheumatoid arthritis disappearing?","volume":"64","author":"Uhlig","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2026.103526_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103932","article-title":"Multiple sclerosis incidence: a systematic review of change over time by geographical region","volume":"63","author":"Lane","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"10","key":"10.1016\/j.jaut.2026.103526_bib9","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1016\/S2665-9913(23)00211-4","article-title":"Global, regional, and national burden of rheumatoid arthritis, 1990-2020, and projections to 2050: a systematic analysis of the global burden of Disease Study 2021","volume":"5","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"Suppl 1","key":"10.1016\/j.jaut.2026.103526_bib10","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/rheumatology\/keac610","article-title":"The global epidemiology of SLE: narrowing the knowledge gaps","volume":"62","author":"Barber","year":"2023","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.jaut.2026.103526_bib11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s44197-025-00353-6","article-title":"Epidemiology of multiple sclerosis: global, regional, national and sub-national-level estimates and future projections","volume":"15","author":"Khan","year":"2025","journal-title":"J Epidemiol Glob Health"},{"issue":"8","key":"10.1016\/j.jaut.2026.103526_bib12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41582-021-00519-3","article-title":"The multiple sclerosis prodrome","volume":"17","author":"Makhani","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jaut.2026.103526_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.899372","article-title":"Preclinical autoimmune disease: a comparison of rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and type 1 diabetes","volume":"13","author":"Frazzei","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.jaut.2026.103526_bib14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/XEB.0000000000000050","article-title":"Guidance for conducting systematic scoping reviews","volume":"13","author":"Peters","year":"2015","journal-title":"Int. J. Evid. Base. Healthc."},{"issue":"7","key":"10.1016\/j.jaut.2026.103526_bib15","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"issue":"9","key":"10.1016\/j.jaut.2026.103526_bib16","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.jaut.2026.103526_bib17","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.jaut.2026.103526_bib18","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2017.19826","article-title":"Effect of hydrolyzed infant formula vs conventional formula on risk of type 1 diabetes: the TRIGR randomized clinical trial","volume":"319","author":"Knip","year":"2018","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.jaut.2026.103526_bib19","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1136\/annrheumdis-2011-200736","article-title":"Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study)","volume":"71","author":"Wevers-de Boer","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"10429","key":"10.1016\/j.jaut.2026.103526_bib20","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(23)02649-1","article-title":"Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial","volume":"403","author":"Cope","year":"2024","journal-title":"Lancet"},{"issue":"10429","key":"10.1016\/j.jaut.2026.103526_bib21","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S0140-6736(23)02650-8","article-title":"Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial","volume":"403","author":"Rech","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jaut.2026.103526_bib22","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/ard.2009.119016","article-title":"Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)","volume":"69","author":"Emery","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jaut.2026.103526_bib23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/rheumatology\/kew357","article-title":"Abatacept reduces disease activity and ultrasound power doppler in ACPA-negative undifferentiated arthritis: a proof-of-concept clinical and imaging study","volume":"56","author":"Buch","year":"2017","journal-title":"Rheumatology"},{"issue":"10348","key":"10.1016\/j.jaut.2026.103526_bib24","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(22)01193-X","article-title":"Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER)","volume":"400","author":"Krijbolder","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jaut.2026.103526_bib25","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2012-202967","article-title":"Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (PROMPT study)","volume":"73","author":"van Aken","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.jaut.2026.103526_bib26","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/annrheumdis-2017-212763","article-title":"Effects of B-cell-directed therapy on the preclinical stage of rheumatoid arthritis (PRAIRI study)","volume":"78","author":"Gerlag","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jaut.2026.103526_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001591","article-title":"Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial","volume":"7","author":"van Boheemen","year":"2021","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.jaut.2026.103526_bib28","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/ard.2008.105767","article-title":"Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial","volume":"69","author":"Bos","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jaut.2026.103526_bib29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13075-015-0912-y","article-title":"Two-year results of DAS-remission-steered treatment strategies aiming at drug-free remission in early arthritis (IMPROVED study)","volume":"18","author":"Heimans","year":"2016","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.jaut.2026.103526_bib30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/annrheumdis-2017-211375","article-title":"Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis (IMPROVED study)","volume":"77","author":"Akdemir","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.jaut.2026.103526_bib31","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/art.40062","article-title":"Clinical trials aiming to prevent rheumatoid arthritis cannot detect prevention without adequate risk stratification: an example using methotrexate vs placebo in undifferentiated arthritis","volume":"69","author":"Burgers","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"7","key":"10.1016\/j.jaut.2026.103526_bib32","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jaut.2026.103526_bib33","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2337\/dc22-2200","article-title":"Abatacept for delay of type 1 diabetes progression in stage 1 relatives at risk: a randomized, double-masked, controlled trial","volume":"46","author":"Russell","year":"2023","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.jaut.2026.103526_bib34","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00125-020-05376-1","article-title":"Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomized controlled trial","volume":"64","author":"Assfalg","year":"2021","journal-title":"Diabetologia"},{"issue":"19","key":"10.1016\/j.jaut.2026.103526_bib35","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2017.17070","article-title":"Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: a randomized clinical trial","volume":"318","author":"Krischer","year":"2017","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.jaut.2026.103526_bib36","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.2015.2928","article-title":"Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial","volume":"313","author":"Bonifacio","year":"2015","journal-title":"JAMA"},{"issue":"583","key":"10.1016\/j.jaut.2026.103526_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc8980","article-title":"Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals","volume":"13","author":"Sims","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/j.jaut.2026.103526_bib38","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.2337\/db21-0519","article-title":"The deterrence of rapid metabolic decline within 3 months after teplizumab treatment in individuals at high risk for type 1 diabetes","volume":"70","author":"Sims","year":"2021","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.jaut.2026.103526_bib39","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2023.2815","article-title":"Teriflunomide and time to clinical multiple sclerosis in patients with radiologically isolated syndrome: the TERIS randomized clinical trial","volume":"80","author":"Lebrun-Fr\u00e9nay","year":"2023","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.jaut.2026.103526_bib40","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ana.26555","article-title":"Dimethyl fumarate delays multiple sclerosis in radiologically isolated syndrome","volume":"93","author":"Okuda","year":"2023","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.jaut.2026.103526_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090509","article-title":"Radiologically isolated syndrome: 5-year risk for an initial clinical event","volume":"9","author":"Okuda","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jaut.2026.103526_bib42","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1186\/s13063-018-3076-7","article-title":"Study of anti-malarials in incomplete lupus erythematosus (SMILE): study protocol for a randomized controlled trial","volume":"19","author":"Olsen","year":"2018","journal-title":"Trials"},{"issue":"10","key":"10.1016\/j.jaut.2026.103526_bib43","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1002\/art.11223","article-title":"Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis","volume":"48","author":"Rantap\u00e4\u00e4-Dahlqvist","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.jaut.2026.103526_bib44","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1002\/art.20431","article-title":"Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis","volume":"50","author":"Nielen","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"23","key":"10.1016\/j.jaut.2026.103526_bib45","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1001\/jama.2013.6285","article-title":"Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children","volume":"309","author":"Ziegler","year":"2013","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.jaut.2026.103526_bib46","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1212\/01.wnl.0000335764.14513.1a","article-title":"Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome","volume":"72","author":"Okuda","year":"2009","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jaut.2026.103526_bib47","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/ana.25799","article-title":"Radiologically isolated syndrome: 10\u2010year risk estimate of a clinical event","volume":"88","author":"Lebrun-Fr\u00e9nay","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jaut.2026.103526_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1455673","article-title":"Screening for autoimmune diseases in apparently healthy antinuclear antibody positive individuals","volume":"11","author":"Andraos","year":"2024","journal-title":"Front. Med."},{"issue":"5","key":"10.1016\/j.jaut.2026.103526_bib49","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40265-023-01847-y","article-title":"Teplizumab: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.jaut.2026.103526_bib50","first-page":"CD011381","article-title":"Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis","volume":"1","author":"Gonzalez-Lorenzo","year":"2024","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.jaut.2026.103526_bib51","doi-asserted-by":"crossref","first-page":"e783","DOI":"10.1212\/WNL.0000000000011242","article-title":"Effect of disease-modifying therapy on disability in relapsing-remitting multiple sclerosis over 15 years","volume":"96","author":"Kalincik","year":"2021","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jaut.2026.103526_bib52","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1177\/13524585241245306","article-title":"Radiologically isolated syndrome in the spectrum of multiple sclerosis","volume":"30","author":"Okuda","year":"2024","journal-title":"Mult. Scler."},{"issue":"10","key":"10.1016\/j.jaut.2026.103526_bib53","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","article-title":"Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria","volume":"24","author":"Montalban","year":"2025","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.jaut.2026.103526_bib54","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3390\/jcm10020243","article-title":"The main challenges in systemic lupus erythematosus: where do we stand?","volume":"10","author":"Piga","year":"2021","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.jaut.2026.103526_bib55","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.semarthrit.2020.11.006","article-title":"From incomplete to complete systemic lupus erythematosus; A review of the predictive serological immune markers","volume":"51","author":"Lambers","year":"2021","journal-title":"Semin. Arthritis Rheum."},{"issue":"16","key":"10.1016\/j.jaut.2026.103526_bib56","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"10441","key":"10.1016\/j.jaut.2026.103526_bib57","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/S0140-6736(24)00398-2","article-title":"Systemic lupus erythematosus","volume":"403","author":"Hoi","year":"2024","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jaut.2026.103526_bib58","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.2337\/db22-0360","article-title":"Islet autoantibody levels differentiate progression trajectories in individuals with presymptomatic type 1 diabetes","volume":"71","author":"Kwon","year":"2022","journal-title":"Diabetes"},{"key":"10.1016\/j.jaut.2026.103526_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.653994","article-title":"Bone erosions detected by ultrasound are prognostic for clinical arthritis development in patients with ACPA and musculoskeletal pain","volume":"8","author":"Ziegelasch","year":"2021","journal-title":"Front. Med."},{"issue":"3","key":"10.1016\/j.jaut.2026.103526_bib60","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2025-005778","article-title":"Windows for intervention in the prearthritis phase of rheumatoid arthritis? A narrative review of key triggering events and potential preventive strategies","volume":"11","author":"Kastbom","year":"2025","journal-title":"RMD Open"},{"issue":"12","key":"10.1016\/j.jaut.2026.103526_bib61","article-title":"Dietary fiber intake associated with risk of rheumatoid arthritis among U.S. adults: NHANES 2010-2020","volume":"102","author":"Liu","year":"2023","journal-title":"Medicine (Baltim.)"},{"issue":"22","key":"10.1016\/j.jaut.2026.103526_bib62","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa012350","article-title":"Effects of insulin in relatives of patients with type 1 diabetes mellitus","volume":"346","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"9413","key":"10.1016\/j.jaut.2026.103526_bib63","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0140-6736(04)15786-3","article-title":"European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomized controlled trial of intervention before the onset of type 1 diabetes","volume":"363","author":"Gale","year":"2004","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jaut.2026.103526_bib64","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2026.103526_bib65","doi-asserted-by":"crossref","DOI":"10.1002\/art.43391","article-title":"A randomized, placebo\u2010controlled trial of hydroxychloroquine in incomplete lupus","author":"Olsen","year":"2025","journal-title":"Arthritis Rheumatol."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841126000041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841126000041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T10:04:27Z","timestamp":1773137067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841126000041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":65,"alternative-id":["S0896841126000041"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2026.103526","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interventional studies targeting the prodromal or preclinical phase of immune-mediated disease to benefit patient outcomes: a scoping review","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2026.103526","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103526"}}